Estimating the Effect of Early Treatment Initiation in Parkinson's Disease Using Observational Data

Both patients and physicians may choose to delay initiation of dopamine replacement therapy in Parkinson's disease (PD) for various reasons. We used observational data to estimate the effect of earlier treatment in PD. Observational data offer a valuable source of evidence, complementary to controlled trials.

[1]  A. Lang,et al.  Initiation of pharmacological therapy in Parkinson's disease: when, why, and how , 2020, The Lancet Neurology.

[2]  Bart Post,et al.  Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial , 2019, The Lancet Neurology.

[3]  B. Bloem,et al.  Quadruple Decision Making for Parkinson’s Disease Patients: Combining Expert Opinion, Patient Preferences, Scientific Evidence, and Big Data Approaches to Reach Precision Medicine , 2019, Journal of Parkinson's disease.

[4]  Bastiaan R Bloem,et al.  Measuring Parkinson's disease over time: The real‐world within‐subject reliability of the MDS‐UPDRS , 2019, Movement disorders : official journal of the Movement Disorder Society.

[5]  A. Lang,et al.  Randomized Delayed‐Start Trial of Levodopa in Parkinson's Disease , 2019, The New England journal of medicine.

[6]  C. Counsell,et al.  Age-related selection bias in Parkinson's disease research: are we recruiting the right participants? , 2018, Parkinsonism & related disorders.

[7]  Nada Lavrac,et al.  Symptoms and medications change patterns for Parkinson's disease patients stratification , 2018, Artif. Intell. Medicine.

[8]  Miguel A Hernán,et al.  How to estimate the effect of treatment duration on survival outcomes using observational data , 2018, British Medical Journal.

[9]  Mark J. van der Laan,et al.  ltmle: An R Package Implementing Targeted Minimum Loss-Based Estimation for Longitudinal Data , 2017 .

[10]  A. Lang,et al.  Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice. , 2017, JAMA neurology.

[11]  J. Schott,et al.  Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study , 2017, The Lancet Neurology.

[12]  D. Faraoni,et al.  Randomized controlled trials vs. observational studies: why not just live together? , 2016, BMC Anesthesiology.

[13]  Arthur W. Toga,et al.  Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson’s Disease , 2015, Journal of Parkinson's disease.

[14]  C. Olanow,et al.  Levodopa: Effect on cell death and the natural history of Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[15]  Stephen R Cole,et al.  The Parametric g-Formula for Time-to-event Data: Intuition and a Worked Example , 2014, Epidemiology.

[16]  A. Gray,et al.  Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. , 2014, Lancet.

[17]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[18]  D. Corcos,et al.  Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humans. , 2013, Contemporary clinical trials.

[19]  W. Poewe,et al.  Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial , 2013, The Lancet Neurology.

[20]  A. Singleton,et al.  The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.

[21]  T. Révész,et al.  Does levodopa accelerate the pathologic process in Parkinson disease brain? , 2011, Neurology.

[22]  J. Pearl,et al.  Causal inference , 2011, Twenty-one Mental Models That Can Change Policing.

[23]  Sherri Rose,et al.  Implementation of G-computation on a simulated data set: demonstration of a causal inference technique. , 2011, American journal of epidemiology.

[24]  Judea Pearl,et al.  Causal Inference , 2010 .

[25]  Werner Poewe,et al.  A double-blind, delayed-start trial of rasagiline in Parkinson's disease. , 2009, The New England journal of medicine.

[26]  S. Silverman,et al.  From randomized controlled trials to observational studies. , 2009, The American journal of medicine.

[27]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.

[28]  J. Robins,et al.  Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments , 2001 .

[29]  J. Robins,et al.  Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.

[30]  J. Hubble,et al.  The effect of deprenyl and levodopa on the progression of Parkinson's disease , 1995, Annals of neurology.

[31]  J. Robins.  A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect , 1986 .